Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31296370 | 0.90 | PSEN1 (0.46) | MAOBCMA1PSEN1PSEN2APH1B | |
| SCHEMBL31300159 | 0.89 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3051430 | 0.83 | ALDH1A1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28260107 | 0.83 | KMT2A (0.43) | DDB1CRBNTSHRSMN1; SMN2HTT | |
| SCHEMBL31300144 | 0.83 | DDB1 (0.41) | DDB1CRBNHTT | |
| SCHEMBL1963328 | 0.83 | CRBN (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL837901 | 0.82 | DDB1 (0.60) | MAOBDDB1CRBN | |
| SCHEMBL31300136 | 0.80 | DDB1 (0.37) | MAOBDDB1CRBNHTT | |
| SCHEMBL7126821 | 0.80 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28206454 | 0.79 | HTT (0.48) | CRBNTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737448-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025060978-A1 | TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-119661547-A | Tricyclic pyridine compounds as SARM1 enzyme activity inhibitors and application thereof | 科辉智药(深圳)新药研究中心有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025002030-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119219603-A | Inhibitors of SARM1 enzyme activity and uses thereof | 科辉智药(深圳)新药研究中心有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-1229343-C | Novel compounds | ASTRAZENECA AB (SE) | 2005-11-30 | — | — | CN | disclosed |
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| CN-1187326-C | Novel compounds | ASTRAZENECA AB (SE) | 2005-02-02 | — | — | CN | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | MAOB 1489/4885CMA1 754/4885PSEN1 4062/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | MAOB 1491/4885CMA1 632/4885PSEN1 3868/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | MAOB 1376/4885CMA1 949/4885PSEN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.